Moderna’s COVID-19 vaccine is 94% effective in preventing symptomatic illness, according to information released Tuesday. The initial review’s findings appear to set the table for federal authorization and nationwide distribution.  

The Food and Drug Administration’s detailed analysis determined the vaccine has a “favorable safety profile.” While there are “no specific safety concerns identified that would preclude issuance of [emergency authorization], side effects are common. They include pain at the site of injection, fatigue, fever and headache.

Should the FDA approve the medication, Americans will soon have two inoculation options. Pfizer-BioNTech’s vaccine was approved Friday, and first shots were given to healthcare workers on Monday.

Distribution of roughly six million doses of Moderna’s vaccine could begin as early as next week. Each vaccine has demonstrated roughly similar effectiveness levels.